Abstract:Background An in situ, gelling, dual drug co-delivery system (PEG-PCL-PEG/DDP + MPEG-PCL/PTX [PDMP]) was prepared through the combination of a cisplatin-containing thermosensitive hydrogel (PEG-PCL-PEG/DDP, PECE/DDP) and paclitaxel-loaded polymeric micelles (MPEG-PCL/PTX micelles). Methods PDMP was a free-flowing solution at ambient temperature and formed a non-flowing gel at body temperature, serving as a drug depot for the in situ treatment of lung cancer. The MPEG-PCL/PTX spherical micelles had a diameter of 20.1 nm and a narrow particle size distribution. Paclitaxel loading and encapsulation efficiency of micelles were 3.96 ± 0.03% and 99.18 ± 0.65%, respectively. Findings Compared with blank micelles, paclitaxel-loaded micelles showed significant tumour inhibition in A549 cells. A xenografted lung cancer model was used to evaluate the antitumour efficiency of PDMP in vivo. PDMP was effective in inhibiting tumour growth and prolonging survival time of tumour-bearing BALB/c nude mice. Immunohistochemical images also showed that tumours in the PDMP group had fewer microvessels and lower proliferation activity compared with the control group. Interpretation Prepared PDMP could have potential for in situ local treatment of lung cancer through in vitro minimal invasive injection. An in situ, gelling, dual drug co-delivery system (PEG-PCL-PEG/DDP + MPEG-PCL/PTX [PDMP]) was prepared through the combination of a cisplatin-containing thermosensitive hydrogel (PEG-PCL-PEG/DDP, PECE/DDP) and paclitaxel-loaded polymeric micelles (MPEG-PCL/PTX micelles). PDMP was a free-flowing solution at ambient temperature and formed a non-flowing gel at body temperature, serving as a drug depot for the in situ treatment of lung cancer. The MPEG-PCL/PTX spherical micelles had a diameter of 20.1 nm and a narrow particle size distribution. Paclitaxel loading and encapsulation efficiency of micelles were 3.96 ± 0.03% and 99.18 ± 0.65%, respectively. Compared with blank micelles, paclitaxel-loaded micelles showed significant tumour inhibition in A549 cells. A xenografted lung cancer model was used to evaluate the antitumour efficiency of PDMP in vivo. PDMP was effective in inhibiting tumour growth and prolonging survival time of tumour-bearing BALB/c nude mice. Immunohistochemical images also showed that tumours in the PDMP group had fewer microvessels and lower proliferation activity compared with the control group. Prepared PDMP could have potential for in situ local treatment of lung cancer through in vitro minimal invasive injection.

Local Delivery of Modified Paclitaxel-Loaded Poly(epsilon-Caprolactone)/pluronic F68 Nanoparticles for Long-Term Inhibition of Hyperplasia.

Modified Paclitaxel-loaded Nanoparticles for Inhibition of Hyperplasia in a Rabbit Arterial Balloon Injury Model

[Surface-Modified Paclitaxel-Loaded Nanoparticles As Local Delivery System for the Prevention of Vessel Restenosis].

In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Photo-crosslinked Poly(ethylene Glycol)-B-poly(ϵ-caprolactone) Nanoparticles for Controllable Paclitaxel Release

Poly(ether-ester Anhydride)-Based Amphiphilic Block Copolymer Nanoparticle As Delivery Devices for Paclitaxel

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis

Metronomic paclitaxel-loaded mPEG–PLA nanoparticles show enhanced anti-tumor efficacy compared to maximum tolerated dose administration

Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance

Primary study on the treatment of rat ovarian carcinoma via the intraperitoneal administration of paclitaxel nanoparticles

Facile fabrication of TPGS-PCL polymeric nanoparticles for paclitaxel delivery to breast cancer: investigation of antiproliferation and apoptosis induction

Safety and Efficacy of A Novel Iopromide-Based Paclitaxel-Eluting Balloon Following Bare Metal Stent Implantation in Rabbit Aorta Abdominalis

P204 A paclitaxel–cisplatin loaded thermosensitive hydrogel for in situ treatment of lung cancer

Evaluation of a Novel Paclitaxel-Eluting Stent with a Bioabsorbable Polymeric Surface Coating in the Porcine Artery Injury Model

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

Enzyme-Sensitive and Amphiphilic PEGylated Dendrimer-Paclitaxel Prodrug-Based Nanoparticles for Enhanced Stability and Anticancer Efficacy

Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models

Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.